Eiger BioPharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Eiger Biopharmaceuticals

14/08/2023 22:43

* Eiger BioPharmaceuticals Inc  EIGR.OQ  reported a
quarterly
adjusted loss of 47 cents​​ per share for the quarter ended in
June. The mean expectation of three analysts for the quarter was
for a loss of 41 cents per share.
    * Revenue rose 13.5% to $4.64 million from a year ago;
analysts
expected $4.57 million. 
    * Eiger BioPharmaceuticals Inc's reported EPS for the
quarter was
a loss of 47 cents​.
    * The mean earnings estimate of analysts had risen by
about 2.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Eiger BioPharmaceuticals Inc shares had fallen by 13.3%
this
quarter and lost 48.3% so far this year.
    * The company reported a quarterly loss of $20.7 million.
    * Wall Street's median 12-month price target for Eiger
BioPharmaceuticals Inc is $4.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 14 at 09:42 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.41          -0.47          Missed
 Mar. 31 2023      -0.47          -0.52          Missed
 Dec. 31 2022      -0.54          -0.57          Missed
 Sep. 30 2022      -0.52          -0.62          Missed